Metabolic phenotyping reveals a reduction in the bioavailability of serotonin and kynurenine pathway metabolites in both the urine and serum of individuals living with Alzheimer’s disease

Luke Whiley; Katie Chappell; Ellie D'Hondt; Matthew Lewis; Beatriz Jimenez; Stuart Snowden; Hilkka  Soininen; Iwona Kloszewska; Patrizia Mecocci; Magda Tsolaki; Bruno Vellas; Jonathan Swann; Abdul  Hye; Simon  Lovestone; Cristina Legido-Quigley; Elaine Holmes

doi:10.1186/s13195-020-00741-z

Metabolic phenotyping reveals a reduction in the bioavailability of serotonin and kynurenine pathway metabolites in both the urine and serum of individuals living with Alzheimer’s disease

Luke Whiley
, Katie Chappell
, Ellie D'Hondt
, Matthew Lewis
, Beatriz Jimenez
, Stuart Snowden
, Hilkka Soininen
, Iwona Kloszewska
, Patrizia Mecocci
, Magda Tsolaki
, Bruno Vellas
, Jonathan Swann
, Abdul Hye
, Simon Lovestone
, Cristina Legido-Quigley
, Elaine Holmes

Department of Biological Sciences

Research output: Contribution to journal › Article › peer-review

Original language	English
Article number	20 (2021)
Journal	Alzheimer's Research and Therapy
Volume	13
DOIs	https://doi.org/10.1186/s13195-020-00741-z
Publication status	Published - 9 Jan 2021

Access to Document

10.1186/s13195-020-00741-zLicence: CC BY

Cite this

Whiley, L., Chappell, K., D'Hondt, E., Lewis, M., Jimenez, B., Snowden, S., Soininen, H., Kloszewska, I., Mecocci, P., Tsolaki, M., Vellas, B., Swann, J., Hye, A., Lovestone, S., Legido-Quigley, C., & Holmes, E. (2021). Metabolic phenotyping reveals a reduction in the bioavailability of serotonin and kynurenine pathway metabolites in both the urine and serum of individuals living with Alzheimer’s disease. Alzheimer's Research and Therapy, 13, Article 20 (2021). https://doi.org/10.1186/s13195-020-00741-z

@article{5c6948bed1304892a7d5598bb18d7a0a,

title = "Metabolic phenotyping reveals a reduction in the bioavailability of serotonin and kynurenine pathway metabolites in both the urine and serum of individuals living with Alzheimer{\textquoteright}s disease",

author = "Luke Whiley and Katie Chappell and Ellie D'Hondt and Matthew Lewis and Beatriz Jimenez and Stuart Snowden and Hilkka Soininen and Iwona Kloszewska and Patrizia Mecocci and Magda Tsolaki and Bruno Vellas and Jonathan Swann and Abdul Hye and Simon Lovestone and Cristina Legido-Quigley and Elaine Holmes",

year = "2021",

month = jan,

day = "9",

doi = "10.1186/s13195-020-00741-z",

language = "English",

volume = "13",

journal = "Alzheimer's Research and Therapy",

issn = "1758-9193",

publisher = "BioMed Central Ltd.",

}

Whiley, L, Chappell, K, D'Hondt, E, Lewis, M, Jimenez, B, Snowden, S, Soininen, H, Kloszewska, I, Mecocci, P, Tsolaki, M, Vellas, B, Swann, J, Hye, A, Lovestone, S, Legido-Quigley, C & Holmes, E 2021, 'Metabolic phenotyping reveals a reduction in the bioavailability of serotonin and kynurenine pathway metabolites in both the urine and serum of individuals living with Alzheimer’s disease', Alzheimer's Research and Therapy, vol. 13, 20 (2021). https://doi.org/10.1186/s13195-020-00741-z

Metabolic phenotyping reveals a reduction in the bioavailability of serotonin and kynurenine pathway metabolites in both the urine and serum of individuals living with Alzheimer’s disease. / Whiley, Luke; Chappell, Katie; D'Hondt, Ellie et al.
In: Alzheimer's Research and Therapy, Vol. 13, 20 (2021), 09.01.2021.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Metabolic phenotyping reveals a reduction in the bioavailability of serotonin and kynurenine pathway metabolites in both the urine and serum of individuals living with Alzheimer’s disease

AU - Whiley, Luke

AU - Chappell, Katie

AU - D'Hondt, Ellie

AU - Lewis, Matthew

AU - Jimenez, Beatriz

AU - Snowden, Stuart

AU - Soininen, Hilkka

AU - Kloszewska, Iwona

AU - Mecocci, Patrizia

AU - Tsolaki, Magda

AU - Vellas, Bruno

AU - Swann, Jonathan

AU - Hye, Abdul

AU - Lovestone, Simon

AU - Legido-Quigley, Cristina

AU - Holmes, Elaine

PY - 2021/1/9

Y1 - 2021/1/9

U2 - 10.1186/s13195-020-00741-z

DO - 10.1186/s13195-020-00741-z

M3 - Article

SN - 1758-9193

VL - 13

JO - Alzheimer's Research and Therapy

JF - Alzheimer's Research and Therapy

M1 - 20 (2021)

ER -